Rubicon Organics Future Growth
Future criteria checks 1/6
Rubicon Organics is forecast to grow revenue at 17.4% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 15.0% |
| Revenue growth rate | 17.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Jun 2026 |
Recent future growth updates
Recent updates
Narrative Update • Mar 13
ROMJ: Cascadia Harvest Ramp Will Support Future Premium Capacity Upside
Analysts kept their fair value estimate for Rubicon Organics steady at CA$1.15, citing unchanged views on the discount rate, revenue growth expectations, profit margin assumptions and long term P/E outlook. What's in the News Rubicon Organics completed the first harvest of cannabis from its new Cascadia facility in Hope, British Columbia, following its acquisition in June 2025 (Key Developments).Narrative Update • Feb 26
ROMJ: Cascadia Facility Ramp Up Will Support Future Premium Capacity Expansion
Analysts have kept their CA$1.15 price target on Rubicon Organics unchanged, citing essentially flat fair value, discount rate, revenue growth, profit margin, and a very high future P/E estimate that remains in place even after the latest refresh of their assumptions. What's in the News Rubicon Organics completed the first harvest of cannabis at its new Cascadia facility in Hope, British Columbia, after acquiring the site in June 2025 and preparing it for commercial production through capital investment and licensing work (Key Developments).Narrative Update • Feb 11
ROMJ: New Permanent CFO Will Support Future Premium Capacity Expansion
Analysts have maintained their fair value estimate for Rubicon Organics at CA$1.15, indicating only very small adjustments to the discount rate, margin, and long-term P/E assumptions rather than any material change in their overall view. What's in the News Rubicon Organics appointed Glen Ibbott as Chief Financial Officer, formalizing his role after serving as interim CFO for about six months (Key Developments).Narrative Update • Jan 27
ROMJ: New Permanent CFO Will Support Premium Capacity Expansion
The analyst price target for Rubicon Organics is unchanged at $1.15, as analysts see only minimal tweaks to inputs such as discount rate, revenue growth and profit margin that do not meaningfully alter their overall view of the shares. What's in the News Rubicon Organics appointed Glen Ibbott as Chief Financial Officer, following a six month period in which he served as interim CFO (Key Developments).Narrative Update • Jan 11
ROMJ: New CFO And Cascadia License Will Support Premium Capacity Expansion
Analysts maintained their price target for Rubicon Organics at $1.15, citing only minor adjustments in their underlying assumptions for discount rate, revenue growth, profit margin and future P/E as the reason for no material change in their valuation view. What's in the News Rubicon Organics appointed Glen Ibbott, a veteran cannabis and life sciences finance executive and former CFO of Aurora Cannabis, as its Chief Financial Officer after serving as interim CFO for six months (Key Developments).Narrative Update • Dec 25
ROMJ: New Licensed Facility Will Drive Premium Capacity Expansion By 2026
Analysts have maintained their price target on Rubicon Organics at approximately $1.15 per share, reflecting largely unchanged assumptions for revenue growth, profitability, and valuation multiples in their updated models. What's in the News Rubicon Organics appointed industry veteran Glen Ibbott, former CFO of Aurora Cannabis, as its new Chief Financial Officer after serving six months in an interim role, bringing over 25 years of public-company finance and cannabis sector experience (Key Developments).Narrative Update • Dec 11
ROMJ: New Facility Expansion Will Support Premium Cannabis Output Growth By 2026
Analysts have maintained their price target for Rubicon Organics at 1.15 dollars, reflecting largely unchanged assumptions for growth, profitability, and valuation multiples in their updated models. What's in the News Rubicon Organics appointed Glen Ibbott, former Aurora Cannabis CFO with over 25 years of life sciences and cannabis finance leadership, as its new Chief Financial Officer after serving six months in an interim capacity (Key Developments).Narrative Update • Nov 27
ROMJ: Cascadia Facility Expansion Will Increase Output by 40% by 2026
Analysts have reaffirmed Rubicon Organics' fair value estimate at $1.15, citing increased revenue growth projections that are balanced by a significant reduction in profit margin expectations. This combination has resulted in minimal change to the overall price target.Narrative Update • Nov 13
ROMJ: Cascadia Facility Expansion Will Drive 40% Output Increase By 2026
Analysts maintained their price target for Rubicon Organics at $1.15. This reflects stable expectations, despite minor adjustments to sector discount rates and growth assumptions.Analysis Article • Nov 02
We Think Rubicon Organics (CVE:ROMJ) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Oct 29
New Facility Will Drive 40% Capacity Increase And Long-Term Upside
Narrative Update on Rubicon Organics Analysts have maintained their fair value price target for Rubicon Organics at $1.15. Recent reassessments indicate minimal changes to underlying growth and profitability assumptions.Narrative Update • Oct 15
Global Cannabis Acceptance And Facility Expansion Will Unlock Long-Term Opportunity
Analysts have revised their price target for Rubicon Organics downward by $0.15 to $1.15 per share, citing tempered revenue growth expectations. This adjustment comes despite a modest improvement in projected profit margins and a lower future price-to-earnings ratio.Narrative Update • Aug 19
International Certifications And Capacity Expansion Will Unlock Premium Cannabis Markets
Driven by notable improvements in both forecasted revenue growth (from 10.6% to 16.3% annually) and net profit margin (from 2.67% to 4.92%), Rubicon Organics' consensus analyst price target has been raised from CA$1.10 to CA$1.30. What's in the News Rubicon Organics launched its new 1964 Supply Co. All-in-One Full Spectrum Extract Resin Vapes in Canada, featuring premium resin and targeting legacy market consumers; two more AIO products are planned by year-end.Analysis Article • Aug 06
Rubicon Organics Inc.'s (CVE:ROMJ) Price Is Out Of Tune With Revenues
TSXV:ROMJ 1 Year Share Price vs Fair Value Explore Rubicon Organics's Fair Values from the Community and select yours...New Narrative • Jun 01
International Certifications And Capacity Expansion Will Unlock Premium Cannabis Markets
Certifications, facility expansion, and new exports position Rubicon Organics for broader international growth, revenue diversification, and increased premium product supply.Analysis Article • Mar 22
Investors Still Aren't Entirely Convinced By Rubicon Organics Inc.'s (CVE:ROMJ) Revenues Despite 37% Price Jump
Rubicon Organics Inc. ( CVE:ROMJ ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Mar 14
Is Rubicon Organics (CVE:ROMJ) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Feb 05
Slammed 30% Rubicon Organics Inc. (CVE:ROMJ) Screens Well Here But There Might Be A Catch
Rubicon Organics Inc. ( CVE:ROMJ ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Dec 22
A Piece Of The Puzzle Missing From Rubicon Organics Inc.'s (CVE:ROMJ) 26% Share Price Climb
Rubicon Organics Inc. ( CVE:ROMJ ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Sep 25
Health Check: How Prudently Does Rubicon Organics (CVE:ROMJ) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jun 08
Rubicon Organics Inc. (CVE:ROMJ) Soars 27% But It's A Story Of Risk Vs Reward
Rubicon Organics Inc. ( CVE:ROMJ ) shares have had a really impressive month, gaining 27% after a shaky period...Analysis Article • May 06
Calculating The Fair Value Of Rubicon Organics Inc. (CVE:ROMJ)
Key Insights Rubicon Organics' estimated fair value is CA$0.32 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Mar 07
Is Rubicon Organics (CVE:ROMJ) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Sep 28
Is Rubicon Organics (CVE:ROMJ) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 13
Benign Growth For Rubicon Organics Inc. (CVE:ROMJ) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Rubicon Organics Inc. ( CVE:ROMJ ) shares are down a considerable 26% in the...Analysis Article • Jun 06
Is Rubicon Organics (CVE:ROMJ) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 99 | N/A | 17 | 20 | 1 |
| 12/31/2027 | 84 | N/A | 9 | 13 | 3 |
| 12/31/2026 | 71 | N/A | -3 | 3 | 3 |
| 3/31/2026 | 61 | -1 | -10 | 0 | N/A |
| 12/31/2025 | 59 | 1 | -11 | -3 | N/A |
| 9/30/2025 | 57 | 3 | -4 | 3 | N/A |
| 6/30/2025 | 55 | 0 | -4 | 3 | N/A |
| 3/31/2025 | 52 | -1 | 1 | 3 | N/A |
| 12/31/2024 | 49 | -3 | 2 | 3 | N/A |
| 9/30/2024 | 44 | -2 | 0 | 2 | N/A |
| 6/30/2024 | 41 | -3 | 0 | 3 | N/A |
| 3/31/2024 | 40 | -3 | 1 | 4 | N/A |
| 12/31/2023 | 40 | -2 | 2 | 5 | N/A |
| 9/30/2023 | 41 | -5 | 3 | 7 | N/A |
| 6/30/2023 | 42 | -2 | 3 | 7 | N/A |
| 3/31/2023 | 39 | -3 | 0 | 4 | N/A |
| 12/31/2022 | 36 | -4 | -2 | 2 | N/A |
| 9/30/2022 | 31 | -2 | -4 | 0 | N/A |
| 6/30/2022 | 28 | -8 | -7 | -3 | N/A |
| 3/31/2022 | 24 | -12 | -10 | -6 | N/A |
| 12/31/2021 | 23 | -15 | -16 | -10 | N/A |
| 9/30/2021 | 21 | -18 | -20 | -14 | N/A |
| 6/30/2021 | 17 | -18 | -22 | -17 | N/A |
| 3/31/2021 | 13 | -15 | -23 | -17 | N/A |
| 12/31/2020 | 9 | -14 | -20 | -14 | N/A |
| 9/30/2020 | 5 | -12 | -21 | -14 | N/A |
| 6/30/2020 | 1 | -11 | -22 | -13 | N/A |
| 3/31/2020 | 0 | -12 | -21 | -12 | N/A |
| 12/31/2019 | N/A | -11 | N/A | -10 | N/A |
| 9/30/2019 | -1 | -9 | N/A | -11 | N/A |
| 6/30/2019 | -1 | -10 | N/A | -11 | N/A |
| 3/31/2019 | 0 | -25 | N/A | -7 | N/A |
| 12/31/2018 | N/A | -25 | N/A | -9 | N/A |
| 9/30/2018 | 2 | -26 | N/A | -10 | N/A |
| 6/30/2018 | 1 | -23 | N/A | -5 | N/A |
| 3/31/2018 | 1 | -8 | N/A | -7 | N/A |
| 12/31/2017 | 1 | -6 | N/A | -4 | N/A |
| 12/31/2016 | 2 | 2 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ROMJ's forecast earnings growth is above the savings rate (3%).
Earnings vs Market: Insufficient data to determine if ROMJ's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if ROMJ's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ROMJ's revenue (17.4% per year) is forecast to grow faster than the Canadian market (4.7% per year).
High Growth Revenue: ROMJ's revenue (17.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ROMJ's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/25 22:28 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rubicon Organics Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nicholas Cortellucci | Atrium Research |
| Ben Pirie | Atrium Research |
| Kimberly Thompson-Hedlin | Canaccord Genuity |